08.01.2013 • NewsInnospecTPCMergers & Acquisitions (M&A)

Innospec Aims for Sub-$300 Million Acquisition by March End

Fuel additives maker Innospec is looking to buy an oilfield specialty company for less than $300 million by the end of the first quarter, its top executive said.

"We are combing all regions to look at small companies that are under $300 million, some public but mostly privately owned," Chief Executive Patrick Williams told Reuters in an interview.

Innospec withdrew its $745 million offer for TPC Group in early December, paving the way for the acquisition of the chemicals maker by private equity firms First Reserve Corp and SK Capital Partners.

Innospec shares have risen about 13% since it dropped the bid that was backed by Blackstone Group.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

most read

Photo
27.03.2025 • News

J&J to Invest $55 Billion in US Operations

US healthcare giant Johnson & Johnson (J&J) has unveiled plans to invest over $55 billion in the US over the next four years. This significant investment marks a 25% increase compared to the previous four years, the company said.

Photo
06.03.2025 • News

CordenPharma Expands Peptide Manufacturing Platform in Switzerland

Contract development and manufacturing organization (CDMO) CordenPharma has finalized plans to establish a new peptide manufacturing facility in Switzerland located at Getec Park in Muttenz near Basel. This investment is part of the company’s growth initiatives with a more than €1 billion strategic investment in peptide development and manufacturing.